At a glance
ClinicalIndex Comparison RecordPhase 2Active· 46 target
Drug / intervention
Relmacabtagene Autoleucel +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT06093841Phase 2ActiveUpdate OverdueUpdated 16mo ago · Completion was 29mo agoEnrollment Stalled
Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL: a Single-arm, Multicenter, Open, Phase II Study
In Brief
A Phase 2 clinical trial evaluating Relmacabtagene Autoleucel, Fludarabine, and 1 other intervention for Lymphoma, Large B-Cell, Diffuse and 3 related conditions. Active but no longer recruiting, targeting 46 participants across 13 sites.
Signals
Enrollment appears stalled
Detailed Summary
The primary objective of this study is to asess the efficacy of Relmacabtagene autoleucel as second-line therapy in adult patients with aggressive B-cell Non-Hodgkins Lymphoma who are ineligible for haematopoietic stem cell transplantation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma, Mediastinal B-Cell Diffuse Large Cell Lymphoma
CountriesChina
Collaborators--
Timeline
Phase 2Active
2024202520262027202820292030
First PostedOct 2023
Enrollment StartNov 2023
Primary CompletionJan 2024
TodayJul 2026
Study CompletionNov 2029
First PostedOct 23, 2023
Enrollment StartNov 3, 2023
Primary CompletionJan 21, 2024
Study CompletionNov 4, 2029
TodayJul 1, 2026
Enrollment to primary: 3 monthsPosted 2.7 years ago
Interventions
Relmacabtagene Autoleucelbiological
A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
Fludarabinedrug
Administered according to package insert
Cyclophosphamidedrug
Administered according to package insert